<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30652752</article-id><article-id pub-id-type="pmc">6326452</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0147</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Perioperative Management of the Diabetic Patient Referred to Cardiac
Surgery</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Arthur</surname><given-names>Camila Perez de Souza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Mej&#x000ed;a</surname><given-names>Omar Asdr&#x000fa;bal Vilca</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Lapenna</surname><given-names>Gisele Aparecida</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Brand&#x000e3;o</surname><given-names>Carlos Manuel de Almeida</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Lisboa</surname><given-names>Luiz Augusto Ferreira</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Dias</surname><given-names>Ricardo Ribeiro</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Dallan</surname><given-names>Lu&#x000ed;s Alberto Oliveira</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Pomerantzeff</surname><given-names>Pablo Maria Alberto</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Jatene</surname><given-names>Fabio B.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><aff id="aff1">
<label>1</label> Cardiovascular Surgery Division, Instituto do
Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina
da Universidade de S&#x000e3;o Paulo (InCor-HCFMUSP), S&#x000e3;o Paulo, SP,
Brazil. </aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Camila Perez de Souza Arthur, Instituto do
Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina
da Universidade de S&#x000e3;o Paulo (InCor-HCFMUSP), Av. Dr. En&#x000e9;as
Carvalho de Aguiar, 44 - Cerqueira C&#x000e9;sar - S&#x000e3;o Paulo, SP, Brazil,
Zip code: 05403-900. E-mail: <email>camilapsarthur@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Nov-Dec</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2018</year></pub-date><volume>33</volume><issue>6</issue><fpage>618</fpage><lpage>625</lpage><history><date date-type="received"><day>22</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><p>Currently there is a progressive increase in the prevalence of diabetes in a
referred for cardiovascular surgery. Benefits of glycemic management (&#x0003c; 180
mg/dL) in diabetic patients compared to patients without diabetes in
perioperative cardiac surgery. The purpose of this study is to present
recommendations based on international evidence and adapted to our clinical
practice for the perioperative management of hyperglycemia in adult patients
with and without diabetes undergoing cardiovascular surgery. This update is
based on the latest current literature derived from articles and guidelines
regarding perioperative management of diabetic patients to cardiovascular
surgery.</p></abstract><kwd-group><kwd>Cardiac Surgery</kwd><kwd>Perioperative Management of the Diabetic Patient</kwd><kwd>Diabetes Mellitus</kwd></kwd-group></article-meta></front><body><table-wrap id="t2" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="41%" span="1"/><col width="3%" span="1"/><col width="10%" span="1"/><col width="36%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#eaeaea" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#eaeaea" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>AACE</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= American
Association of Clinical Endocrinologists</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>HbA1c</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Hemoglobin
A1c</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ACCORD</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Action to Control
Cardiovascular Risk in Diabetes</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ICU</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Intensive care
unit</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ADA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= American Diabetes
Association</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ITA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Internal thoracic
artery</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ADVANCE</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Action in Diabetes
and Vascular Disease: Preterax</bold><break/><bold>and Diamicron MR
Controlled Evaluation</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>NICE-SUGAR</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Normoglycemia in
Intensive Care Evaluation-</bold><break/><bold>Survival Using
Glucose Algorithm Regulation</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>AIA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Anterior
interventricular artery</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>NPH</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Neutral protamine
Hagedorn</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>BITA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Bilateral internal
thoracic artery</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>SBD</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Brazilian Society
of Diabetes</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>CABG</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Coronary artery
bypass grafting</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>SITA</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Single internal
thoracic artery</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>DIGAMI</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Diabetes and
insulin-glucose infusion in acute myocardial infarction</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>SVG</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Saphenous vein
grafting</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>EASD</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= European
Association for the Study of Diabetes</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>VADT</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Veterans Affair
Diabetes Trial</bold></td></tr><tr><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>ECC</bold></td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1"><bold>= Extracorporeal
circulation</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#eaeaea" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Diabetic patients have a higher risk of undergoing any type of surgical intervention
compared to the non-diabetic population. Additionally, after the procedure, they
also present higher perioperative morbidity and mortality<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Currently, there is a
progressive increase in the prevalence of diabetes in patients referred for
cardiovascular surgery. Besides higher perioperative morbidity and mortality, these
patients present lower angina-free survival and a significant decrease in long-term
survival<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>]</sup>. In this scenario, evidence shows that appropriate
glycemic management can improve these outcomes.</p><p>Insulin deficiency and insulin resistance are known to be aggravated by surgery and
anesthesia and may lead to lipolysis and ketogenesis, which may result in metabolic
acidosis and subsequent electrolyte changes. Protein catabolism increases due to
increased degradation and decreased synthesis. Insulin administration may reverse
most of these disorders, so, in type 2 diabetic patients, long-acting sulfonylureas,
like chlorpropamide, should be discontinued and replaced with agents of short
duration. Metformin should always be discontinued. Type 2 diabetic patients with
marked hyperglycemia and on oral treatment should receive insulin prior to surgery.
Insulin requirements may range from 0.25-0.40 U per gram of glucose in diabetic
patients with normal weight undergoing surgery to 0.4-0.8 U per gram of glucose in
diabetic patients with obesity, liver disease, on treatment with steroids, or
sepsis, and 0.8-1.2 U per gram of glucose in diabetic patients undergoing surgery
with use of extracorporeal circulation (ECC). Therefore, the appropriate dose should
be personalized, knowing that the protocol preferred by most authors is based on the
variable rate of insulin infusion.</p><p>Next, we will present recommendations based on international evidence and adapted to
our clinical practice for the perioperative management of hyperglycemia in adult
patients with and without diabetes undergoing cardiovascular surgery at the
Instituto do Cora&#x000e7;&#x000e3;o da Faculdade de Medicina da Universidade de
S&#x000e3;o Paulo.</p></sec><sec><title>PERIOPERATIVE HYPERGLYCEMIA</title><p>The limitation in glycemic management is associated with increased morbidity and
mortality.</p><p>McAlister et al.<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup> found, in a retrospective analysis of 291 patients
undergoing coronary artery bypass grafting (CABG), that the mean blood glucose level
on the first postoperative day adequately predicted the development of an adverse
outcome. Harmful effects with elevated intraoperative blood glucose levels were also
reported by Gandhi et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> in a retrospective study of 409 patients undergoing
cardiac surgery. In this study, pre- and intraoperative hyperglycemias were
independent risk factors for perioperative complications, including death.</p><p>A retrospective study of 6280 patients undergoing cardiac procedures found that high
blood glucose levels were a predictor of mortality in patients with and without
diabetes<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Fish et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> showed that glycemic levels above 250
mg/dL increased 10 times the number of complications in patients undergoing
CABG.</p><p>Finally, Anderson et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> showed that, in 1375 patients undergoing CABG,
preoperative hyperglycemia increased by twice the mortality rate in one year
compared to patients with normal preoperative blood glucose.</p><p>Together, these studies strongly suggest that hyperglycemia during the perioperative
period of cardiovascular surgery is a predictor of morbidity and mortality,
regardless of whether or not the patient is diabetic. Next, we will present
recommendations supported by evidence of how the reduction of blood glucose levels
decreases the incidence of negative outcomes in this group of patients.</p><p>Individualization is the key point in elderly population, per the Brazilian Society
of Diabetes (SBD), the American Diabetes Association (ADA), and the European
Association for the Study of Diabetes (EASD), the fasting glycemic value is up to
150 mg/dL, the postprandial glycemic value is &#x0003c; 180 mg/dL, and the less stringent
hemoglobin A1c (HbA1c) goal is &#x0003c; 8%. According to the critical analysis of four
major studies - United Kingdom Prospective Diabetes Study (UKPDS), Action in
Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation
(ADVANCE), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Veterans
Affair Diabetes Trial (VADT) - the attempt to rigorously control the glycemia in
elderly patients, especially in those with known atherosclerotic diseases, in
addition to not preventing cardiovascular events, may increase mortality (ACCORD),
possibly but not necessarily due to hypoglycemia. Therefore, the SBD recommends that
an overall assessment should be made of each case in order to flexibilize or
consolidate the therapeutic targets, following the same principles
described<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p></sec><sec><title>IMPACT OF GLYCEMIC MANAGEMENT ON CLINICAL RESULTS DURING CARDIAC SURGERY</title><p>Benefits of glycemic management (&#x0003c; 180 mg/dL) in diabetic patients during cardiac
surgery:</p><p>
<list list-type="bullet"><list-item><p>It reduces mortality;</p></list-item><list-item><p>It reduces morbidity;</p></list-item><list-item><p>It decreases the incidence of wound infection;</p></list-item><list-item><p>It reduces hospital stay;</p></list-item><list-item><p>It increases long-term survival.</p></list-item></list>
</p><p>The impact of glycemic management during heart surgery was reported by Furnary et
al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>
analyzing 3554 patients undergoing CABG between 1987 and 2001. Patients were divided
into three groups: from 1987 to 1991, they received insulin subcutaneously once
every 4 hours to maintain blood glucose level at 200 mg/dL; from 1991 to 1998,
continuous intravenous insulin infusion was used to maintain blood glucose levels
between 150 and 200 mg/dL; and from 1998 to 2001, the Portland protocol was
instituted, administering continuous insulin drip to maintain blood glucose levels
between 100 and 150 mg/dL. Continuous infusions of insulin resulted in lower mean
glucose levels than that obtained with intermittent subcutaneous insulin therapy.
From 1992 and after the establishment of continuous insulin protocols, perioperative
mortality in diabetic patients undergoing CABG was reduced by 50% (4.5%
<italic>vs</italic>. 1.9%, <italic>P</italic>=0.0001), which was similar to that
of non-diabetic patients undergoing CABG. There was also a significant decrease in
the incidence of surgical wound infections (<italic>P</italic>=0.001). Furnary et
al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>
expanded its original series to include an additional population of 1980 patients
treated with the Portland protocol between 2001 and 2005. They introduced a new
method for assessing glycemic management, called "Glucose 3", which consisted of the
mean glucose values obtained in surgery and on the first and second postoperative
days. An increase in "Glucose 3" was an independent predictor of perioperative
mortality (<italic>P</italic>&#x0003c;0.001). On the other hand, this value was also
related to an increase in the incidence of deep infections of the sternum, time of
hospitalization, blood transfusions, atrial fibrillation, and low cardiac output
syndrome.</p><p>The importance of the use of insulin in diabetic patients undergoing CABG was
presented by Lazar et al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> and consists of a modified glucose, insulin, and
potassium solution. In this study, 141 diabetic patients undergoing CABG were
randomized to receive glucose, insulin, and potassium to maintain a blood glucose
level between 120 and 180 mg/dL or a mobile insulin scale to maintain glucose level
&#x0003c; 250 mg/dL. The combination of glucose, insulin, and potassium was initiated in
the induction of anesthesia and continued for 12 hours in the intensive care unit
(ICU). This protocol obtained better glycemic management immediately before
cardiopulmonary bypass (169 mg/dL <italic>vs</italic>. 209 mg/dL,
<italic>P</italic>&#x0003c;0.0001) and after 12 hours in the ICU (134 mg/dL
<italic>vs</italic>. 266 mg/dL, <italic>P</italic>&#x0003c;0.0001). Patients treated
with strict glycemic control had higher cardiac indices
(<italic>P</italic>&#x0003c;0.0001) and less need for vasoactive drugs
(<italic>P</italic>&#x0003c;0.05) and cardiac stimulation
(<italic>P</italic>&#x0003c;0.05). Strict glycemic control resulted in a lower incidence
of infections (0 <italic>vs</italic>. 13%, <italic>P</italic>=0.01) and atrial
fibrillation (15% <italic>vs</italic>. 60%, <italic>P</italic>=0.007). All this
contributed to the reduction of hospitalization time (6.5 days <italic>vs</italic>.
9.2 days, <italic>P</italic>=0.0003). After five years, Kaplan-Meier curves showed
survival advantage (<italic>P</italic>=0.04) for patients who received better
glycemic control. They had a lower incidence of recurrent angina
(<italic>P</italic>=0.01), wound infection (<italic>P</italic>=0.03), and were able
to maintain a lower class of angina (<italic>P</italic>=0.03).</p><p>Evidence on the importance of rigorous glycemic management in patients undergoing
CABG has also been demonstrated in a study by Van den Berghe et
al.<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>, involving 1548 patients on mechanical ventilation
admitted to a surgical ICU. In this prospective, randomized study, 62% of the
patients underwent cardiac surgery and only 13% had a history of diabetes. Patients
were randomized into a conventional therapeutic group, in which insulin was
administered only if the blood glucose level was &#x0003e; 215 mg/dL to maintain a target
of 180-200 mg/dL, and into another group that received continuous infusion of
insulin to maintain glucose levels between 80 and 110 mg/dL. Intensive insulin
therapy resulted in a significant reduction in mortality (10% <italic>vs</italic>.
20%, <italic>P</italic>=0.005). Cardiac surgery mortality was only reduced in those
patients who required three days of ICU care. Hospital mortality for all cardiac
surgery patients, regardless of ICU stay, was reduced from 5.1% to 2.1%
(<italic>P</italic>&#x0003c;0.05). Intensive glycemic management had no effect on the
morbidity and mortality of patients who stayed more than three days in the ICU. In
another study to identify patients who could benefit more from strict glycemic
management, D'Alessandro et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup> sought to correlate the effect of strict
glycemic management with the results expected by EuroSCORE in diabetic patients
undergoing CABG. Using the propensity score, 300 diabetic patients undergoing CABG
who received strict glycemic management (150 to 200 mg/dL in the operating room, 140
mg/dL in the ICU) and 300 diabetic patients undergoing CABG when the insulin
protocols did not yet exist were compared. The rigid glycemic management group had a
significantly lower mortality than that expected by EuroSCORE (1.3%
<italic>vs</italic>. 4.3%, <italic>P</italic>=0.01). Mortality was low, mainly
in the highest risk group (EuroSCORE 4; 2.5% <italic>vs</italic>. 8.0%,
<italic>P</italic>=0.03). In contrast, there was no difference between observed
and expected mortalities in the group without strict glycemic management in patients
with EuroSCORE &#x0003c; 4. Two other additional studies showed the importance of
glycemic management in reducing sternal infection. Zerr et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> studied the effects of
glycemic management on the incidence of sternal infection in 1585 diabetic patients
undergoing CABG. Sternal infection increased by 1.3% in patients with mean glucose
values of 100 to 150 mg/dL to 6.7% in patients with levels of 250 to 300 mg/dL. In a
retrospective study of diabetic patients undergoing CABG, Hruska et
al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup> observed that continuous infusion of insulin
maintaining blood glucose levels between 120 and 160 mg/dL significantly reduced the
incidence of sternal infection compared with intermittent subcutaneous
injections.</p></sec><sec><title>GLYCEMIC MANAGEMENT DURING CARDIAC SURGERY IN NON-DIABETIC PATIENTS</title><p>Intraoperative glycemic management with continuous infusion of intravenous insulin is
not necessary in non-diabetic patients undergoing cardiac surgery, provided that
blood glucose levels remain &#x0003c; 180 mg/dL.</p><p>Is rigorous glycemic control necessary for all patients undergoing cardiovascular
surgery?</p><p>Butterworth et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> showed the effects of strict blood glucose control
in 381 non-diabetic patients undergoing isolated CABG. In this prospective,
randomized study, one group received continuous infusion of insulin when
intraoperative blood glucose levels were &#x0003e; 100 mg/dL. The other group did not
receive insulin coverage. The primary outcome was the incidence of new neurological
events, neuro-ophthalmologic and neurobehavioral deficits, and neurological-related
deaths. Intraoperative blood glucose levels were significantly lower in patients
receiving insulin infusion, although there was no difference in the incidence of
neurological complications. Likewise, there were no differences between the groups
regarding operative mortality, need for vasoactive drugs, and time of
hospitalization; however, patients who did not receive intraoperative insulin had
blood glucose levels at 200 mg/dL. In this study, intraoperative glycemic management
did not improve short- and long-term clinical outcomes in the non-diabetic patients'
group.</p><p>Gandhi et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup> studied the effects of intensive intraoperative
insulin therapy in 400 patients undergoing elective CABG. Patients were randomized
prospectively into a group with continuous insulin, to maintain blood glucose levels
between 80 and 100 mg/dL, and into a conventional group, to maintain blood glucose
levels up to 200 mg/dL using intermittent boluses of intravenous insulin. The
incidence of diabetes was 20% in both groups. There was no difference between the
groups in the composite outcome: death, sternal infection, prolonged ventilation,
cardiac arrhythmias, stroke, and renal failure up to 30 days after surgery. There
was also no difference in ICU time and hospital admission between the groups. And
there was a tendency for more deaths (<italic>P</italic>=0.06) and stroke
(<italic>P</italic>=0.02) in the intensive care group with insulin. The
limitations of this study were the inclusion of patients with and without diabetes
and that both groups received intensive insulin therapy in the immediate
postoperative period.</p></sec><sec><title>PERIOPERATIVE HYPERGLYCEMIA MANAGEMENT USING INSULIN PROTOCOLS</title><sec><title>Recommendation: Class I</title><p>
<list list-type="bullet"><list-item><p>Glycemic management is best achieved with continuous insulin
infusions instead of subcutaneous injections of insulin or
intermittent intravenous insulin bolus (level of evidence A).</p></list-item><list-item><p>All diabetic patients undergoing cardiac surgery should receive
continuous insulin infusion during surgery and for at least 24 hours
postoperatively to maintain blood glucose levels &#x02264; 180 mg/dL
(level of evidence B).</p></list-item></list>
</p><p>Intravenous insulin therapy is the preferred method for perioperative insulin
administration. It allows rapid titration, facilitating glycemic management
during periods of malabsorption and deficiency or insulin
resistance<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. <xref rid="t1" ref-type="table">Table 1</xref>
describes various protocols available for the use of insulin and the glycemic
values that can be achieved.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Types of insulin infusion protocols.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="60%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Glycemic control protocol</th><th align="center" rowspan="1" colspan="1">Brief description</th><th align="center" rowspan="1" colspan="1">mg/dL</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Markovitz</td><td align="left" rowspan="1" colspan="1">Five algorithms with precalculated rates using the
multiplier; infusion rates are determined by blood glucose
range</td><td align="center" rowspan="1" colspan="1">120-199</td></tr><tr><td align="left" rowspan="1" colspan="1">Leuven</td><td align="left" rowspan="1" colspan="1">General guidelines on insulin drip titration</td><td align="center" rowspan="1" colspan="1">80-110</td></tr><tr><td align="left" rowspan="1" colspan="1">Yale</td><td align="left" rowspan="1" colspan="1">Calculated rates based on glycemic value and rates
of change</td><td align="center" rowspan="1" colspan="1">90-120</td></tr><tr><td align="left" rowspan="1" colspan="1">Portland</td><td align="left" rowspan="1" colspan="1">Specific infusion rates in insulin boluses
according to blood glucose level; five<break/>categories are
available for ICU and infirmary</td><td align="center" rowspan="1" colspan="1">70-110<break/>80-120<break/>100-150<break/>125-175<break/>150-200</td></tr><tr><td align="left" rowspan="1" colspan="1">DIGAMI</td><td align="left" rowspan="1" colspan="1">Specific rates of insulin infusion per blood
glucose range</td><td align="center" rowspan="1" colspan="1">126-180</td></tr><tr><td align="left" rowspan="1" colspan="1">Washington University</td><td align="left" rowspan="1" colspan="1">Four algorithms with rates precalculated by the
multiplier; infusion rates are determined by blood glucose
range</td><td align="center" rowspan="1" colspan="1">80-180</td></tr><tr><td align="left" rowspan="1" colspan="1">Atlanta Medical Center</td><td align="left" rowspan="1" colspan="1">Ten algorithms with rates precalculated by
multiplier; infusion rates are determined by blood glucose
range</td><td align="center" rowspan="1" colspan="1">80-110</td></tr><tr><td align="left" rowspan="1" colspan="1">Glucommander</td><td align="left" rowspan="1" colspan="1">Infusion rates calculated by computer according to
programmed algorithms</td><td align="center" rowspan="1" colspan="1">80-120</td></tr><tr><td align="left" rowspan="1" colspan="1">Clarian</td><td align="left" rowspan="1" colspan="1">Infusion rates calculated by computer according to
algorithms programmed by GlucoStabilizer</td><td align="center" rowspan="1" colspan="1">80-110</td></tr><tr><td align="left" rowspan="1" colspan="1">Matias</td><td align="left" rowspan="1" colspan="1">Infusion rates calculated by computer according to
based algorithm of absolute glucose value</td><td align="center" rowspan="1" colspan="1">80-110</td></tr><tr><td align="left" rowspan="1" colspan="1">eMPC</td><td align="left" rowspan="1" colspan="1">Infusion rates calculated by computer based on
model of predictive control algorithm with variable sampling
rate</td><td align="center" rowspan="1" colspan="1">80-110</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>DIGAMI=diabetes and insulin-glucose infusion in acute myocardial
infarction; ICU=intensive care unit</p></fn><attrib>Source: Friedberg et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>, 2006 and update<sup>[<sup><xref rid="r20" ref-type="bibr">20</xref></sup>,<sup><xref rid="r21" ref-type="bibr">21</xref></sup>]</sup>.</attrib></table-wrap-foot></table-wrap><p>The choice of a specific protocol depends on the needs and resources of the
institution. Thus, to ensure the effective and safe execution of any protocol,
individuals involved in patient care should feel comfortable.</p><p>The success of any protocol can be determined based on results such as: the time
taken to reach the target value, the specific concentrations of glycemic
handling, the mean blood glucose level, the percentage of blood glucose levels
desired, or the calculation of an area under the curve of the percentage of time
taken to reach a certain interval<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>. This issue is specifically
addressed by the American Association of Clinical Endocrinologists (AACE) on the
management of hyperglycemia in the hospital<sup>[<xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r24" ref-type="bibr">24</xref>]</sup>. Also, for
patient's follow-up and safety, the number (or percentage) of hypoglycemic
events and any other intercurrence should be recorded.</p></sec></sec><sec><title>PREOPERATIVE MANAGEMENT AND EVALUATION FOR DIABETIC PATIENTS</title><sec><title>Recommendations:</title><sec><title>Class I</title><p>
<list list-type="bullet"><list-item><p>Diabetic patients receiving continuous insulin (lispro, aspart,
glulisine, or regular) should maintain it until after dinner in
the night before surgery (level of evidence B).</p></list-item><list-item><p>The schedule of insulin therapy to achieve glycemic management
should be initiated using a combination of short- and
long-acting subcutaneous insulin or an insulin infusion protocol
in hospitalized patients awaiting surgery (level of evidence
C).</p></list-item><list-item><p>All hypoglycemic agents and non-insulin oral diabetes medications
should be maintained up to 24 hours before surgery (level of
evidence C).</p></list-item><list-item><p>The level of glycated HbA1c should be assessed prior to surgery
in patients with diabetes or those at risk for postoperative
hyperglycemia to characterize the level of preoperative glycemic
management (level of evidence C).</p></list-item></list>
</p></sec><sec><title>Class II</title><p>
<list list-type="bullet"><list-item><p>Before surgery, it is reasonable to maintain blood glucose level
&#x02264; 180 mg/dL (level of evidence B).</p></list-item></list>
</p><p>Efforts should be made to optimize glycemic control prior to surgery and to
avoid an increase in morbidity, including a higher incidence of surgical
wound infections and an increase in the postoperative
period<sup>[<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>. In general, all oral antidiabetic
agents should be discontinued 24 hours before surgery, especially
sulfonylureas (<italic>e.g</italic>., glipizide) and glinides
(<italic>e.g</italic>., nateglinide or repaglinide). These drugs can
induce hypoglycemia in the absence of food. Patients who take insulin and
are admitted on the day of surgery should be instructed to continue basal
insulin use (<italic>e.g</italic>., glargine, detemir, or neutral protamine
Hagedorn [NPH]) and maintain insulin by nutritional need
(<italic>e.g</italic>., lispro, aspart, glulisine, or regular), unless
it is contraindicated by the responsible physician. Before surgery, NPH
insulin can be reduced by half or one third to prevent hypoglycemia. To
achieve rapid control in the hospitalized patient with hyperglycemia
(persistent glycemia &#x0003e; 180 mg/dL for a period &#x0003e; 12 hours prior to
surgery), insulin therapy should be used either by continuous rapid
intravenous or subcutaneous infusion.</p><p>In hyperglycemic patients, on the day of surgery, intravenous insulin therapy
is an effective alternative to achieve rapid control. In addition, patients
with a known history of diabetes (type 1 or 2) may initiate preoperative
intravenous therapy. The patient should be questioned about other
medications used preoperatively, because of their potential for insulin
resistance. These include steroids, protease inhibitors, and antipsychotic
medications. It is also necessary to emphasize the importance of the
identification of patients with kidney failure because the decrease of
insulin clearance increases the risk of hypoglycemia.</p><p>Glycosylated HbA1c is an accurate indicator of glycemic control over a period
of 2 to 3 months. ADA reports that adequate glycemic control is associated
with an HbA1c &#x02264; 7%<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. Therefore, preoperative assessment of
HbA1c in diabetic patients or at risk of postoperative hyperglycemia helps
to optimize the glycemic management of those with elevated levels of HbA1c.
Hence, it facilitates the identification of patients who may require more
aggressive glycemic management after discharge from hospital.</p></sec></sec></sec><sec><title>INTRAOPERATIVE MANAGEMENT</title><sec><title>Recommendations:</title><sec><title>Class I</title><p>
<list list-type="bullet"><list-item><p>Blood glucose levels &#x0003e; 180 mg/dL in non-diabetic patients
occurring solely during ECC may be initially treated with single
or intermittent intravenous insulin dosing as long as blood
glucose levels &#x02264; 180 mg/dL are maintained. However, in
patients with persistently elevated blood glucose levels (&#x0003e;
180 mg/dL) after ECC, insulin drip should be instituted and
requested to be evaluated by an endocrinologist (level of
evidence B).</p></list-item><list-item><p>If infusion of intravenous insulin is initiated preoperatively,
it should be continued throughout intraoperative and immediate
postoperative periods according to institutional protocols to
maintain blood glucose level &#x02264; 180 mg/dL (level of
evidence C).</p></list-item></list>
</p><p>Patients receiving infusion of intravenous insulin should have their blood
glucose monitored every 30 to 60 minutes. A monitoring every 15 minutes
should be performed for periods of rapid sensitivity change, such as during
cardioplegia administration and in cooling or systemic heating. Patients who
started preoperative intravenous infusion should continue intraoperatively
to maintain a blood glucose level &#x02264; 180 mg/dL.</p><p>Patients with no history of diabetes may present transient elevation of blood
glucose level (&#x0003e; 180 mg/dL) during ECC. These patients may have insulin
resistance and should be treated with a single or intermittent dose of
insulin to maintain blood glucose level &#x02264; 180 mg/dL. We should be
cautious in initiating continuous intravenous insulin in these cases,
because insulin requirements may decrease rapidly in the immediate
postoperative period, resulting in severe hypoglycemia<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. However,
non-diabetic patients with persistently elevated blood glucose levels (&#x0003e;
180 mg/dL) during surgery should receive insulin drip. As a large percentage
of these patients may develop diabetes, the evaluation of the
endocrinologist should be obtained postoperatively.</p></sec></sec></sec><sec><title>STRATEGIES FOR MYOCARDIAL REVASCULARIZATION SURGERY IN DIABETIC PATIENTS</title><p>
<list list-type="order"><list-item><p>The FREEDOM study was designed to evaluate the benefits of current
angioplasty techniques (which uses drug-eluting stents) and of CABG in
combination with aggressive drug therapy in diabetic
patients<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>. The results of overall mortality,
acute myocardial infarction, and stroke were significantly lower in the
surgery group. This study confirmed that CABG is the preferred
revascularization strategy in diabetic patients.</p></list-item><list-item><p>Since the 1980s, grafting with the internal thoracic artery (ITA) or
mammary artery to the anterior interventricular artery (AIA) or anterior
descending artery has significantly increased survival and it is
associated with a lower incidence of late cardiac events and a better
quality of life in a 10-year follow-up<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>. This
benefit results from a higher long-term patency of ITA when compared to
saphenous vein grafts.</p></list-item><list-item><p>The use of ITAs (double mammary) is associated with better survival rate
compared to the use of a single ITA in both diabetic and non-diabetic
patients. However, studies show that the use of ITAs is associated with
a higher occurrence of deep sternal infection in relation to the use of
a single ITA. This risk of deep sternal infection is counterbalanced by
a long-term benefit, as it has recently been reported in the literature
that deep sternal infection did not limit the benefit of ITAs in the
long-term<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>. In addition, the risk of infection can
be minimized by modifying the technique of ITAs dissection. In this
sense, the skeletonization of ITA (<italic>i.e</italic>., isolated
dissection of ITA) is preferable to the removal of the pedicled ITA
(<italic>i.e</italic>., including tissue and vein) and thus,
collateral branches and vascularization of the sternum can be preserved,
with improvement in infection rates of the sternum, particularly in
diabetic patients.</p></list-item><list-item><p>The ESC/EACTS 2014 guidelines on myocardial revascularization recommend
that the use of both ITAs should be considered in patients younger than
70 years of age (Class IIa). The guidelines also establish that, in
diabetic patients with multiarterial coronary disease and with
acceptable surgical risk, CABG is recommended for percutaneous coronary
intervention (Class I) and that the use of both ITAs should be
considered in these patients. Thus, all diabetic patients younger than
70 years of age, without morbid obesity, and whose HbA1c dosage is &#x0003c;
7% should receive double mammary graft. On the other hand, skeletonized
dissection of ITAs is recommended<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>.</p></list-item><list-item><p>A sub-analysis of the ROOBY study compared the clinical evolution between
CABG with and without the use of ECC in diabetic patients. This analysis
showed higher rates of incomplete revascularization that correlated with
an increase in the rates of adverse events and 30-day mortality in
diabetic patients operated on without ECC. In addition, in this group of
patients, graft patency at one year was significantly lower in non-ECC
surgeries (83.1%) than in ECC surgeries (88.4%)<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup> (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Survival curves after CABG in diabetic patients. Each symbol
represents a death at 1, 3, 5, 10, 15, and 20 years after
surgery as estimated by Kaplan-Meier. Vertical bars are
confidence intervals with standard error of &#x000b1; 1.
Continuous lines are parametric estimates within
intermittent lines with standard error &#x000b1; 1. A:
Stratification by both ITAs (BITA and SITA) isolated and
only saphenous vein (SVG). B: Stratification according to
complete versus incomplete revascularization. C:
Stratification according to CABG with ECC (onpump) and CABG
without ECC (off-pump) <sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>.</p><p>BITA=bilateral internal thoracic artery; CABG=coronary artery
bypass grafting; ECC=extracorporeal circulation;
ITA=internal thoracic artery; SITA=single internal thoracic
artery; SVG=saphenous vein grafting</p></caption><graphic xlink:href="rbccv-33-06-0618-g01"/></fig>
</p></list-item></list>
</p></sec><sec><title>GLYCEMIC MANAGEMENT IN ICU</title><sec><title>Recommendations: Class I</title><p>
<list list-type="bullet"><list-item><p>Patients with or without diabetes and persistently elevated blood
glucose levels (&#x0003e; 180 mg/dL) should receive intravenous insulin
infusions to maintain blood glucose levels &#x02264; 180 mg/dL during
their stay in ICU (level of evidence A).</p></list-item><list-item><p>Patients requiring &#x02265; 3 days in ICU due to ventilator
dependence or the need for inotropes, continuous venovenous
hemodialysis or hemofiltration, and antiarrhythmic intra-aortic
balloon or left ventricular assist device should receive continuous
infusion of intravenous insulin to maintain a blood glucose level
&#x0003c; 150 mg/dL, regardless of whether or not they are diabetics
(level of evidence B).</p></list-item><list-item><p>Before discontinuing continuous infusion of intravenous insulin,
patients should be scheduled for subcutaneous insulin administration
using institutional protocols (level of evidence B).</p></list-item></list>
</p><p>Persistently elevated glucose levels in patients with or without previous
diabetes ) should receive intravenous infusion of insulin to maintain blood
glucose levels &#x02264; 180 mg/dL.Those requiring a time greater than or equal
to 3 days of ICU, prolonged ventilatory support, inotropic drugs or technical
support, renal insufficiency, antiarrhythmic therapy should be infused with
continuous insulin to maintain a blood glucose level of &#x0003c;150 mg/dL
<sup>[<xref rid="r11" ref-type="bibr">11</xref>-<xref rid="r13" ref-type="bibr">13</xref>]</sup>.</p><p>Patients receiving continuous infusion of intravenous insulin in ICU should have
their blood glucose monitored at least every hour until they are stable. This
frequency avoids fluctuations in blood glucose levels and minimizes the risk of
hypoglycemia, which fortunately is a rare complication with minimal risk of
morbidity<sup>[<xref rid="r11" ref-type="bibr">11</xref>-<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Once patients are scheduled to be discharged
from the ICU, they should switch to a subcutaneous insulin regimen. Daily
insulin requirements can be calculated based on the average amount of insulin
required in the last 24 hours and the patients' new nutritional
regimen<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>.</p><p>The Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm
Regulation (NICE-SUGAR) compared two glycemic control strategies based on
insulin (target blood glucose &#x0003c;180 mg/dL in the control group and a range of
81-108 mg/dL in the intervention group) in a sample of 6104 ICU patients. In
this study, the intensive blood glucose control was associated with higher
cardiovascular mortality, with an absolute difference of 5.8%. Kansagara et
al.<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup> reported that intensive postoperative blood
glucose control was associated with a reduction in the composite endpoint of
all-cause mortality, myocardial infarction, and acute heart failure.</p><p>Moderately strict glycemic control added to the usual standard of care in
patients undergoing cardiac surgery were associated with a 6% reduction in
infection rates and a 12% reduction in atrial fibrillation, with no differences
between groups in terms of mortality<sup>[<xref rid="r32" ref-type="bibr">32</xref>]</sup>.</p></sec></sec><sec><title>GLYCEMIC MANAGEMENT IN THE WARD</title><sec><title>Recommendations: Class I</title><p>
<list list-type="bullet"><list-item><p>A maximum blood glucose level &#x0003c; 180 mg/dL should be achieved in
the postprandial state (level of evidence B).</p></list-item><list-item><p>A fasting and before meals blood glucose level of &#x02264; 110 mg/dL
should be reached after transfer to the ward (level of evidence
C).</p></list-item><list-item><p>Oral antidiabetics should be restarted in patients with adequate
blood glucose levels, with few exceptions. Consequently, insulin
doses should be reduced (level of evidence C).</p></list-item><list-item><p>According to the AACE, a reasonable goal for a noncritical patient in
a hospital ward is fasting glucose &#x0003c; 110 mg/dL and postprandial
glucose &#x0003c; 180 mg/dL<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>. On the other hand,
the best method to achieve this control is with programmed
subcutaneous insulin (glargine or determir) or bolus therapy
(lispro, aspart, or glulisine). Patients with type 2 diabetes who
take preoperative oral antidiabetics may restart these medications
after reaching adequate blood glucose levels and starting a regular
diet. However, metformin should not be restarted until it reaches a
stable renal function. Glitazones cannot be restarted in patients
with congestive heart failure or hepatic dysfunction.</p></list-item></list>
</p></sec></sec><sec><title>PREPARATION FOR HOSPITAL DISCHARGE</title><sec><title>Recommendations: Class I</title><p>
<list list-type="bullet"><list-item><p>Before discharge, all patients with diabetes and those who started a
new glycemic management regimen should receive guidance on blood
glucose monitoring, drug administration, diet, and lifestyle changes
(level of evidence C).</p></list-item><list-item><p>After discharge, changes in glycemic control therapy should be
reported to primary care physicians and an endocrinologist
appointment should be scheduled if necessary (level of evidence
C).</p></list-item></list>
</p><p>All patients with hyperglycemia after cardiac surgery should be evaluated by a
diabetes team to define glycemic control after discharge. When hyperglycemia is
first discovered in the perioperative period, if insulin is administered for the
first time, or when a new insulin protocol is instituted, the patient should
receive expert advice before discharge. Guidance on glycemic monitoring, drug
administration, feeding, exercise, and lifestyle changes should be initiated at
least two days before discharge<sup>[<xref rid="r33" ref-type="bibr">33</xref>-<xref rid="r35" ref-type="bibr">35</xref>]</sup>.</p></sec></sec><sec><title>FUTURE RESEARCH AREAS</title><p>Important issues regarding the management of hyperglycemia during cardiovascular
surgery should still be elucidated. In this scenario, future research will
determine: (1) the ideal level of glycemic management and, if appropriate, the most
important perioperative period to maintain this control; (2) whether the blood
glucose level reached is as important as the amount of insulin delivered; (3) the
importance of preoperative levels of HbA1c and whether surgery should be postponed
in patients with high HbA1c levels; (4) if the handling of elderly patients should
be protocolized or individualized, could them tolerate higher levels of HbA1c
without risk morbidities or their increased risk of hypoglycemia is so higher than
of the general population that a more permissive HbA1c would significantly reduce
their morbidity and mortality? Answers to these questions will increase our
understanding of hyperglycemia during cardiovascular surgery and will help us
determine more appropriate methods to achieve glycemic control and improve clinical
outcomes in this group of high-risk patients.</p><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="7%" span="1"/><col width="93%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1"><bold>Authors&#x02019; roles &#x00026;
responsibilities</bold></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CPSA</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; drafting the work or revising it critically for
important intellectual content</td></tr><tr><td align="left" rowspan="1" colspan="1">OAVM</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; drafting the work or revising it critically for
important intellectual content</td></tr><tr><td align="left" rowspan="1" colspan="1">GAL</td><td align="left" rowspan="1" colspan="1">Drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">CMAB</td><td align="left" rowspan="1" colspan="1">Drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">LAFL</td><td align="left" rowspan="1" colspan="1">Drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">RRD</td><td align="left" rowspan="1" colspan="1">Drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">LAOD</td><td align="left" rowspan="1" colspan="1">Drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">PMAP</td><td align="left" rowspan="1" colspan="1">Drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">FBJ</td><td align="left" rowspan="1" colspan="1">Drafting the work or revising it critically for
important intellectual content; final approval of the version to be
published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Cardiovascular Surgery Division, Instituto do
Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina
da Universidade de S&#x000e3;o Paulo (InCor-HCFMUSP), S&#x000e3;o Paulo, SP,
Brazil.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Kerner</surname><given-names>W</given-names></name></person-group><article-title>Perioperative management of the diabetic patient</article-title><source>Exp Clin Endocrinol Diabetes</source><year>1995</year><volume>103</volume><issue>4</issue><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">7584526</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szab&#x000f3;</surname><given-names>Z</given-names></name><name><surname>Hakanson</surname><given-names>E</given-names></name><name><surname>Svedjeholm</surname><given-names>R</given-names></name></person-group><article-title>Early postoperative outcome and medium-term survival in 540
diabetic and 2239 nondiabetic patients undergoing coronary artery bypass
grafting</article-title><source>Ann Thorac Surg</source><year>2002</year><volume>74</volume><issue>3</issue><fpage>712</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">12238829</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>JL</given-names></name><name><surname>Scholz</surname><given-names>PM</given-names></name><name><surname>Chen</surname><given-names>AY</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Gold</surname><given-names>J</given-names></name><name><surname>Schneider</surname><given-names>SH</given-names></name></person-group><article-title>Diabetes mellitus increases short-term mortality and morbidity in
patients undergoing coronary artery bypass graft surgery</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>40</volume><issue>3</issue><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">12142105</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAlister</surname><given-names>FA</given-names></name><name><surname>Man</surname><given-names>J</given-names></name><name><surname>Bistritz</surname><given-names>L</given-names></name><name><surname>Amad</surname><given-names>H</given-names></name><name><surname>Tandon</surname><given-names>P</given-names></name></person-group><article-title>Diabetes and coronary artery bypass surgery: an examination of
perioperative glycemic control and outcomes</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><issue>5</issue><fpage>1518</fpage><lpage>1524</lpage><pub-id pub-id-type="pmid">12716815</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandhi</surname><given-names>GY</given-names></name><name><surname>Nuttall</surname><given-names>GA</given-names></name><name><surname>Abel</surname><given-names>MD</given-names></name><name><surname>Mullany</surname><given-names>CJ</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Intraoperative hyperglycemia and perioperative outcomes in
cardiac surgery patients</article-title><source>Mayo Clin Proc</source><year>2005</year><volume>80</volume><issue>7</issue><fpage>862</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">16007890</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doenst</surname><given-names>T</given-names></name><name><surname>Wijeysundera</surname><given-names>D</given-names></name><name><surname>Karkouti</surname><given-names>K</given-names></name><name><surname>Zechner</surname><given-names>C</given-names></name><name><surname>Maganti</surname><given-names>M</given-names></name><name><surname>Rao</surname><given-names>V</given-names></name><etal/></person-group><article-title>Hyperglycemia during cardiopulmonary bypass is an independent
risk factor for mortality in patients undergoing cardiac
surgery</article-title><source>J Thorac Cardiovasc Surg</source><year>2005</year><volume>130</volume><issue>4</issue><fpage>1144</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">16214532</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fish</surname><given-names>LH</given-names></name><name><surname>Weaver</surname><given-names>TW</given-names></name><name><surname>Moore</surname><given-names>AL</given-names></name><name><surname>Steel</surname><given-names>LG</given-names></name></person-group><article-title>Value of postoperative blood glucose in predicting complications
and length of stay after coronary artery bypass grafting</article-title><source>Am J Cardiol</source><year>2003</year><volume>92</volume><issue>1</issue><fpage>74</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">12842253</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>RE</given-names></name><name><surname>Brismar</surname><given-names>K</given-names></name><name><surname>Barr</surname><given-names>G</given-names></name><name><surname>Ivert</surname><given-names>T</given-names></name></person-group><article-title>Effects of cardiopulmonary bypass on glucose homeostasis after
coronary artery bypass surgery</article-title><source>Eur J Cardiothorac Surg</source><year>2005</year><volume>28</volume><issue>3</issue><fpage>425</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">16054822</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Sociedade Brasileira de Diabetes</collab></person-group><source>Diretrizes da Sociedade Brasileira de Diabetes 2017-2018</source><year>2017</year><publisher-loc>S&#x000e3;o Paulo</publisher-loc><publisher-name>Clannad</publisher-name><size units="pages">383p</size></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furnary</surname><given-names>AP</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Grunkemeier</surname><given-names>GL</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zerr</surname><given-names>KJ</given-names></name><name><surname>Bookin</surname><given-names>SO</given-names></name><etal/></person-group><article-title>Continuous insulin infusion reduces mortality in patients with
diabetes undergoing coronary artery bypass grafting</article-title><source>J Thorac Cardiovasc Surg</source><year>2003</year><volume>125</volume><issue>5</issue><fpage>1007</fpage><lpage>1021</lpage><pub-id pub-id-type="pmid">12771873</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furnary</surname><given-names>AP</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Bookin</surname><given-names>SO</given-names></name></person-group><article-title>Effect of hyperglycemia and continuous intravenous insulin
infusions on outcomes of cardiac surgical procedures: the Portland Diabetic
Project</article-title><source>Endocr Pract</source><year>2004</year><volume>10</volume><issue>Suppl. 2</issue><fpage>21</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15251637</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazar</surname><given-names>HL</given-names></name><name><surname>Chipkin</surname><given-names>SR</given-names></name><name><surname>Fitzgerald</surname><given-names>CA</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Cabral</surname><given-names>H</given-names></name><name><surname>Apstein</surname><given-names>CS</given-names></name></person-group><article-title>Tight glycemic control in diabetic coronary artery bypass graft
patients improves perioperative outcomes and decreases recurrent ischemic
events</article-title><source>Circulation</source><year>2004</year><volume>109</volume><issue>12</issue><fpage>1497</fpage><lpage>1502</lpage><pub-id pub-id-type="pmid">15006999</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Berghe</surname><given-names>G</given-names></name><name><surname>Wouters</surname><given-names>P</given-names></name><name><surname>Weekers</surname><given-names>F</given-names></name><name><surname>Verwaest</surname><given-names>C</given-names></name><name><surname>Bruyninckx</surname><given-names>F</given-names></name><name><surname>Schetz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Intensive insulin therapy in the critically ill
patients</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>19</issue><fpage>1359</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">11794168</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Alessandro</surname><given-names>C</given-names></name><name><surname>Leprince</surname><given-names>P</given-names></name><name><surname>Golmard</surname><given-names>JL</given-names></name><name><surname>Ouattara</surname><given-names>A</given-names></name><name><surname>Aubert</surname><given-names>S</given-names></name><name><surname>Pavie</surname><given-names>A</given-names></name><etal/></person-group><article-title>Strict glycemic control reduces EuroSCORE expected mortality in
diabetic patients undergoing myocardial revascularization</article-title><source>J Thorac Cardiovasc Surg</source><year>2007</year><volume>134</volume><issue>1</issue><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">17599483</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerr</surname><given-names>KJ</given-names></name><name><surname>Furnary</surname><given-names>AP</given-names></name><name><surname>Grunkemeier</surname><given-names>GL</given-names></name><name><surname>Bookin</surname><given-names>S</given-names></name><name><surname>Kanhere</surname><given-names>V</given-names></name><name><surname>Starr</surname><given-names>A</given-names></name></person-group><article-title>Glucose control lowers the risk of wound infection in diabetics
after open heart operations</article-title><source>Ann Thorac Surg</source><year>1997</year><volume>63</volume><issue>2</issue><fpage>356</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">9033300</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hruska</surname><given-names>LA</given-names></name><name><surname>Smith</surname><given-names>JM</given-names></name><name><surname>Hendy</surname><given-names>MP</given-names></name><name><surname>Fritz</surname><given-names>VL</given-names></name><name><surname>McAdams</surname><given-names>S</given-names></name></person-group><article-title>Continuous insulin infusion reduces infectious complications in
diabetics following coronary surgery</article-title><source>J Card Surg</source><year>2005</year><volume>20</volume><issue>5</issue><fpage>403</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">16153268</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butterworth</surname><given-names>J</given-names></name><name><surname>Wagenknecht</surname><given-names>LE</given-names></name><name><surname>Legault</surname><given-names>C</given-names></name><name><surname>Zaccaro</surname><given-names>DJ</given-names></name><name><surname>Kon</surname><given-names>ND</given-names></name><name><surname>Hammon Jr</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Attempted control of hyperglycemia during cardiopulmonary bypass
fails to improve neurologic or neurobehavioral outcomes in patients without
diabetes mellitus undergoing coronary artery bypass grafting</article-title><source>J Thorac Cardiovasc Surg</source><year>2005</year><volume>130</volume><issue>5</issue><fpage>1319</fpage><lpage>1319</lpage><pub-id pub-id-type="pmid">16256784</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandhi</surname><given-names>GY</given-names></name><name><surname>Nuttall</surname><given-names>GA</given-names></name><name><surname>Abel</surname><given-names>MD</given-names></name><name><surname>Mullany</surname><given-names>CJ</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name><name><surname>O'Brien</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Intensive intraoperative insulin therapy versus conventional
glucose management during cardiac surgery: a randomized
trial</article-title><source>Ann Intern Med</source><year>2007</year><volume>146</volume><issue>4</issue><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">17310047</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedberg</surname><given-names>SJ</given-names></name><name><surname>Lam</surname><given-names>YW</given-names></name><name><surname>Blum</surname><given-names>JJ</given-names></name><name><surname>Gregerman</surname><given-names>RI</given-names></name></person-group><article-title>Insulin absorption: a major factor in apparent insulin resistance
and the control of type 2 diabetes mellitus</article-title><source>Metabolism</source><year>2006</year><volume>55</volume><issue>5</issue><fpage>614</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">16631437</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hovorka</surname><given-names>R</given-names></name><name><surname>Kremen</surname><given-names>J</given-names></name><name><surname>Blaha</surname><given-names>J</given-names></name><name><surname>Matias</surname><given-names>M</given-names></name><name><surname>Anderlova</surname><given-names>K</given-names></name><name><surname>Bosanska</surname><given-names>L</given-names></name><etal/></person-group><article-title>Blood glucose control by a model predictive control algorithm
with variable sampling rate versus a routine glucose management protocol in
cardiac surgery patients: a randomized controlled trial</article-title><source>J Clin Endocrinol Metab</source><year>2007</year><volume>92</volume><issue>8</issue><fpage>2960</fpage><lpage>2964</lpage><pub-id pub-id-type="pmid">17550955</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaha</surname><given-names>J</given-names></name><name><surname>Kopecky</surname><given-names>P</given-names></name><name><surname>Matias</surname><given-names>M</given-names></name><name><surname>Hovorka</surname><given-names>R</given-names></name><name><surname>Kunstyr</surname><given-names>J</given-names></name><name><surname>Kotulak</surname><given-names>T</given-names></name><etal/></person-group><article-title>Comparison of three protocols for tight glycemic control in
cardiac surgery patients</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><issue>5</issue><fpage>757</fpage><lpage>761</lpage><pub-id pub-id-type="pmid">19196894</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braithwaite</surname><given-names>SS</given-names></name><name><surname>Godara</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>HJ</given-names></name><name><surname>Rock</surname><given-names>P</given-names></name></person-group><article-title>No patient left behind: evaluation and design of intravenous
insulin infusion algorithms</article-title><source>Endocr Pract</source><year>2006</year><volume>12</volume><issue>Suppl 3</issue><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">16905521</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>PA</given-names></name><name><surname>Bozzo</surname><given-names>JE</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Mesmer</surname><given-names>MM</given-names></name><name><surname>Sakharova</surname><given-names>OV</given-names></name><name><surname>Radford</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>"Glucometrics": assessing the quality of inpatient glucose
management</article-title><source>Diabetes Technol Ther</source><year>2006</year><volume>8</volume><issue>5</issue><fpage>560</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">17037970</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><article-title>American Diabetes Association &#x00026; Pharmacologic approaches to
glycemic treatment: Standards of Medical Care in Diabetes -
2018</article-title><source>Diabetes Care</source><year>2018</year><volume>41</volume><issue>Suppl.1</issue><fpage>S73</fpage><lpage>S85</lpage><pub-id pub-id-type="pmid">29222379</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaney</surname><given-names>MA</given-names></name><name><surname>Nikolov</surname><given-names>MP</given-names></name><name><surname>Blakeman</surname><given-names>BP</given-names></name><name><surname>Bakhos</surname><given-names>M</given-names></name></person-group><article-title>Attempting to maintain normoglycemia during cardiopulmonary
bypass with insulin may initiate postoperative hypoglycemia</article-title><source>Anesth Analg</source><year>1999</year><volume>89</volume><issue>5</issue><fpage>1091</fpage><lpage>1095</lpage><pub-id pub-id-type="pmid">10553817</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farkouh</surname><given-names>ME</given-names></name><name><surname>Domanski</surname><given-names>M</given-names></name><name><surname>Sleeper</surname><given-names>LA</given-names></name><name><surname>Siami</surname><given-names>FS</given-names></name><name><surname>Dangas</surname><given-names>G</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><collab>FREEDOM Trial Investigators</collab></person-group><article-title>Strategies for multivessel revascularization in patients with
diabetes</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><issue>25</issue><fpage>2375</fpage><lpage>2384</lpage><pub-id pub-id-type="pmid">23121323</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raza</surname><given-names>S</given-names></name><name><surname>Sabik 3rd</surname><given-names>JF</given-names></name><name><surname>Masabni</surname><given-names>K</given-names></name><name><surname>Ainkaran</surname><given-names>P</given-names></name><name><surname>Lytle</surname><given-names>BW</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name></person-group><article-title>Surgical revascularization techniques that minimize surgical risk
and maximize late survival after coronary artery bypass grafting in patients
with diabetes mellitus</article-title><source>J Thorac Cardiovasc Surg</source><year>2014</year><volume>148</volume><issue>4</issue><fpage>1257</fpage><lpage>1264</lpage><pub-id pub-id-type="pmid">25260269</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jatene</surname><given-names>FB</given-names></name><name><surname>Kolh</surname><given-names>P</given-names></name></person-group><article-title>Bilateral internal thoracic artery grafts for myocardial
revascularization in insulin dependent diabetic patients: time for wide
clinical practice?</article-title><source>Eur J Cardiothorac Surg</source><year>2015</year><volume>48</volume><issue>1</issue><fpage>121</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">25501320</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shroyer</surname><given-names>AL</given-names></name><name><surname>Hattler</surname><given-names>B</given-names></name><name><surname>Wagner</surname><given-names>TH</given-names></name><name><surname>Baltz</surname><given-names>JH</given-names></name><name><surname>Collins</surname><given-names>JF</given-names></name><name><surname>Carr</surname><given-names>BM</given-names></name><collab>VA #517 Randomized On/Off Bypass (ROOBY) Study Group</collab></person-group><article-title>Comparing off pump and on pump clinical outcomes and costs for
diabetic cardiac surgery patients</article-title><source>Ann Thorac Surg</source><year>2014</year><volume>98</volume><issue>1</issue><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">24841548</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmeltz</surname><given-names>LR</given-names></name><name><surname>DeSantis</surname><given-names>AJ</given-names></name><name><surname>Schmidt</surname><given-names>K</given-names></name><name><surname>O'Shea-Mahler</surname><given-names>E</given-names></name><name><surname>Rhee</surname><given-names>C</given-names></name><name><surname>Brandt</surname><given-names>S</given-names></name><etal/></person-group><article-title>Conversion of intravenous insulin infusions to subcutaneously
administered insulin glargine in patients with hyperglycemia</article-title><source>Endocr Pract</source><year>2006</year><volume>12</volume><issue>6</issue><fpage>641</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">17229660</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kansagara</surname><given-names>D</given-names></name><name><surname>Fu</surname><given-names>R</given-names></name><name><surname>Freeman</surname><given-names>M</given-names></name><name><surname>Wolf</surname><given-names>F</given-names></name><name><surname>Helfand</surname><given-names>M</given-names></name></person-group><article-title>Intensive insulin therapy in hospitalized patients: a systematic
review</article-title><source>Ann Intern Med</source><year>2011</year><volume>154</volume><issue>4</issue><fpage>268</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">21320942</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viana</surname><given-names>MV</given-names></name><name><surname>Moraes</surname><given-names>RB</given-names></name><name><surname>Fabbrin</surname><given-names>AR</given-names></name><name><surname>Santos</surname><given-names>MF</given-names></name><name><surname>Gerchman</surname><given-names>F</given-names></name></person-group><article-title>Assessment and treatment of hyperglycemia in critically ill
patients</article-title><source>Rev Bras Ter Intensiva</source><year>2014</year><volume>26</volume><issue>1</issue><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">24770692</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loures</surname><given-names>DRR</given-names></name><name><surname>Carvalho</surname><given-names>RG</given-names></name><name><surname>Mulinari</surname><given-names>L</given-names></name><name><surname>Silva Jr.</surname><given-names>AZ</given-names></name><name><surname>Schmidlin</surname><given-names>CA</given-names></name><name><surname>Brommelstr&#x000f6;et</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cardiac surgery in elderly patients</article-title><source>Rev Bras Cir Cardiovasc</source><year>2000</year><volume>15</volume><issue>1</issue><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>SH</given-names></name><name><surname>Song</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>SR</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Shin</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Long-term effects of a structured intensive diabetes education
programme (SIDEP) in patients with type 2 diabetes mellitus: a 4-year
follow-up study</article-title><source>Diabet Med</source><year>2007</year><volume>24</volume><issue>1</issue><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">17227325</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritsche</surname><given-names>A</given-names></name><name><surname>Stumvoll</surname><given-names>M</given-names></name><name><surname>Goebbel</surname><given-names>S</given-names></name><name><surname>Reinauer</surname><given-names>KM</given-names></name><name><surname>Schm&#x000fc;lling</surname><given-names>RM</given-names></name><name><surname>H&#x000e4;ring</surname><given-names>HU</given-names></name></person-group><article-title>Long term effect of a structured inpatient diabetes teaching and
treatment programme in type 2 diabetic patients: influence of mode of
follow-up</article-title><source>Diabetes Res Clin Pract</source><year>1999</year><volume>46</volume><issue>2</issue><fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">10724092</pub-id></element-citation></ref></ref-list></back></article>